• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-K/A filed by Lite Strategy Inc.

    11/20/25 5:29:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email
    8-K/A
    true000126210400012621042025-11-142025-11-14

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K/A

    Amendment No. 1

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 14, 2025

     

     

    Lite Strategy, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41827

    51-0407811

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd.,

    Suite 150

     

    San Diego, California

     

    92121

    (Address of principal executive Offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: 858 369-7100

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.00000002 par value

     

    LITS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Explanatory Note

    This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 18, 2025 (the Original Form 8-K) by Lite Strategy, Inc. (the Company), to correct information regarding the number of shares of the Company's common stock $0.00000002 par value (the Common Stock), issuable upon the exercise of stock options granted to Justin J. File on such date in connection with his appointment as Chief Executive Officer of the Company.

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    In the Original Form 8-K, the Company reported that the Board of Directors (the Board) granted Mr. File options (the Options) to purchase 635,000 shares of the Common Stock under the Company’s Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (the Equity Plan). The actual number of shares of Common Stock issuable upon exercise of the options granted to Mr. File was 180,000 shares.

    On November 20, 2025, the Board approved a grant to Mr. File of options (the Replacement Options) to purchase 455,000 shares of Common Stock, with such options to have an exercise price per share equal to the greater of (a) the closing price of the Common Stock on Nasdaq on the date of grant and (b) $2.02 (which is the exercise price per share of the Options granted on November 14, 2025). The closing price of the Common Stock on Nasdaq on November 20, 2025 was $1.70, and the Replacement Options thus have an exercise price per share of $2.02. The Replacement Options otherwise have the same terms as, and shall vest on the same schedule as, the options to purchase 180,000 shares of Common Stock granted to Mr. File on November 14, 2025; provided that the Replacement Options shall be granted under, and subject to and contingent upon approval by the Company’s stockholders of, a new omnibus equity plan to replace the Equity Plan (the New Omnibus Plan), and the Replacement Options shall be cancelled if the New Omnibus Plan is not approved by the Company’s stockholders at the annual meeting of stockholders for the fiscal year 2026.

    Except as described above, no other changes have been made to the Original Form 8-K, and this amendment does not modify or update any other information contained in the Original Form 8-K. This amendment should be read in conjunction with the Original Form 8-K.

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    LITE STRATEGY, INC.

     

     

     

     

    Date:

    November 20, 2025

    By:

    /s/ Justin J. File

     

     

     

    Chief Executive Officer, Chief Financial Officer and Secretarty

     


    Get the next $LITS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company's digital asset treasury strategy as well as its pharmaceutical operations. "Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus," Board Member Charlie Lee said. "We recently celebrated Litecoin's 14th anniversary and its unblemished track record of reliability and uptime. LITS provides inv

    11/17/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

    SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS"), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, joins the digital asset community in celebrating the 14th anniversary of Litecoin (LTC), and its role as the second-longest-running blockchain in crypto and a model of network resilience. "As we celebrate this historic time, we see that Litecoin's 14-year track record of reliability and uptime continues to attract more institutional interest. As institutions look for digital assets with proven durability and sound hard-money principles, Litecoin stands out as a strong choice for both treasury divers

    10/16/25 4:06:43 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    Amendment: SEC Form 8-K/A filed by Lite Strategy Inc.

    8-K/A - Lite Strategy, Inc. (0001262104) (Filer)

    11/20/25 5:29:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Lite Strategy Inc.

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    11/18/25 5:07:13 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lite Strategy Inc.

    10-Q - Lite Strategy, Inc. (0001262104) (Filer)

    11/14/25 4:30:50 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4/A - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 5:29:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glover Nicholas

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/19/25 1:41:38 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care